Fed. Circ. Upholds Axing Pfizer Vax IP But Calls For More Info
The Patent Trial and Appeal Board rightly invalidated most of a Pfizer flu vaccine patent but was too hasty in its analysis when refusing to amend the patent, the Federal Circuit...To view the full article, register now.
Already a subscriber? Click here to view full article